HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Could the motor unit number index be an early prognostic biomarker for amyotrophic lateral sclerosis?

AbstractOBJECTIVE:
To evaluate the associations between motor unit number index (MUNIX) and disease progression and prognosis in amyotrophic lateral sclerosis (ALS) in a large-scale longitudinal study.
METHODS:
MUNIX was performed at the patient's first visit, at 3, 6, and 12 months in 4 muscles. MUNIX data from the patients were compared with those from 38 age-matched healthy controls. Clinical data included the revised ALS functional rating scale (ALSFRS-R), the forced vital capacity (FVC), and the survival of the patients.
RESULTS:
Eighty-two patients were included at baseline, 62 were evaluated at three months, 48 at six months, and 33 at twelve months. MUNIX score was lower in ALS patients compared to controls. At baseline, MUNIX was correlated with ALSFRS-R and FVC. Motor unit size index (MUSIX) was correlated with patient survival. Longitudinal analyses showed that MUNIX decline was greater than ALSFRS-R decline at each evaluation. A baseline MUNIX score greater than 378 predicted survival over the 12-month period with a sensitivity of 82% and a specificity of 56%.
CONCLUSIONS:
This longitudinal study suggests that MUNIX could be an early quantitative marker of disease progression and prognosis in ALS.
SIGNIFICANCE:
MUNIX might be considered as potential indicator for monitoring disease progression.
AuthorsAude-Marie Grapperon, Vincent Harlay, Mohamed Boucekine, David Devos, Anne-Sophie Rolland, Claude Desnuelle, Emilien Delmont, Annie Verschueren, Shahram Attarian
JournalClinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology (Clin Neurophysiol) Vol. 163 Pg. 47-55 (Apr 26 2024) ISSN: 1872-8952 [Electronic] Netherlands
PMID38703699 (Publication Type: Journal Article)
CopyrightCopyright © 2024. Published by Elsevier B.V.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: